Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Germany
Poland
Turkey
DPem
Dimethylfumarate for the treatment of bullous pemphigoid

Project Coordinator

University of Lübeck
Lübeck
Germany

Partners

Antonio Martinez Immungenetics AG Rostock, Germany
Philippe Bernard Hôpital Robert Debré Reims, France
Yayli Savas Karadeniz Technical University School of Medicine Trabzon, Turkey
Cezary Kowalewski Medical University of Warsaw Warszawa, Poland

Bullous pemphigoid (BP) is a rare autoimmune blistering disease occuring in the elderly. Patients suffer from intense itching and skin inflammation. There is no cure for BP. Corticosteroids rapidly clear symptoms, but do not cure the disease. Hence, they have to be applied for prolonged times. This is poorly tolerated in the elderly patient population, and is one major reason for death. Hence, there is a so far high unmet medical need for the development of safe and effective treatments for BP. Dimethyl fumarate (DMF), originally derived from the herbal plant Fumaria officinalis, has been licensed for psoriasis. In pre-clinical models of BP and similar pemphigoid diseases, we showed that DMF is therapeutically active. Based on this observation, we here will test the efficacy and safety of adjuvant DMF in BP. We expect that patients who receive additional DMF will require lower doses of corticosteroids, experience less relapses, and survive longer.

E-Rare 2012 - Created by Toussaint Biger